Table 2—

Randomised trials of second-line treatment of small cell lung cancer

RegimenYearPhasePatients nResponse rate %TTPweeksSurvival weeks[Ref.]
CAV versus topotecan1999II104/10718/241/017/2412/20/25/2571
Topotecan, oral versus intravenous2001II52/5423/152/421/1119/3015/1332/2575
Topotecan, oral versus intravenous2007III155/15418/221/017/2218/2312/1533/3574
Oral topotecan/BSC versus BSC alone2006III71/707/0/7/44/16/26/1473
  • Time to progression (TTP) and survival are presented as medians. OR: overall response; CR: complete response; PR: partial response; SD: stable disease; CAV: cyclophosphamide, doxorubicin and vincristine; BSC: best supportive care.